Cancer drugs present strongest innovation pipeline in next 5 years: Report
Immuno-oncology (IO) drugs or cancer therapeutics represent one of the most promising areas of medical innovation in the next five years, according to a report on Friday.
The report by GlobalData, a data and analytics company, based on a survey of 128 pharma industry professionals, showed that the innovation will fundamentally transform how cancer is treated.
“Advancements in immunotherapy such as checkpoint inhibitors, CAR-T cell therapies, cancer vaccines, etc., are revolutionising the way cancer is treated,” Urte Jakimaviciute, Senior Director of Market Research and Strategic Intelligence in the healthcare division at GlobalData.
Jakimaviciute noted that these therapies will evolve to lead “to more effective and personalised treatments”.
Further, “high unmet needs in cancer with many types of indications lacking effective treatments are driving and will continue to drive the innovation in immuno-oncology/ cancer therapeutics,” Jakimaviciute said.